Highlights

Share

Program Content

Activities

  • IAS Preview
    IAS 2019: A Preview of Key Data to Be Presented in Mexico City
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 16, 2019

  • New Data From IAS 2019
    Clinical Impact of New Data From IAS 2019
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 02, 2019

  • IAS 2019: Looking Ahead
    Looking Ahead From IAS 2019: New Hope For HIV Prevention and Treatment
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 26, 2019

  • LA Injectable CAB + RPV
    Long-Acting Injectable ART: What Do Patients Think?
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 12, 2019

Activities

ANRS 12300 Reflate TB2
ANRS 12300 Reflate TB2: RAL + 3TC/TDF Does Not Achieve Noninferior Efficacy vs EFV + 3TC/TDF at Wk 48 in ART-Naive Adults With HIV and TB
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 23, 2019

GEMINI
GEMINI-1 and -2: DTG + 3TC Noninferior to DTG + FTC/TDF at Wk 96 in ART-Naive Adults
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2019

Tsepamo
Tsepamo: DTG Exposure at Conception Associated With Smaller Increase in Incidence of Neural Tube Defects in Updated Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2019

BRIGHTE
BRIGHTE: Wk 96 Results From Phase III Study of Fostemsavir + OBT in Heavily Treatment–Experienced Patients Failing Current ART
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2019

ATLAS: PROs With LA-ART
ATLAS: Patient-Reported Outcomes From Phase III Study of Switch to Long-Acting Injectable Cabotegravir + Rilpivirine in Virologically Suppressed Patients
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 25, 2019

Switch to BIC/FTC/TAF
Study 380-4030: Switch to BIC/FTC/TAF Noninferior to DTG + FTC/TAF in Virologically Suppressed Adults
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2019

DISCOVER: TFV-DP Levels
DISCOVER: More Rapid and Sustained Protective Levels of TFV-DP With FTC/TAF vs FTC/TDF as PrEP
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2019

TANGO
TANGO: Switch to DTG/3TC Noninferior to Continued TAF-Based ART in Virologically Suppressed Adults
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2019

Islatravir + Doravirine
DRIVE2Simplify, Part 2: Wk 48 Results From Phase IIb study of Islatravir + Doravirine vs DOR/3TC/TDF in ART-Naive Adults
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 29, 2019

ADVANCE
ADVANCE: DTG + FTC/(TAF or TDF) Noninferior to EFV/FTC/TDF in ART-Naive Patients in South Africa
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 29, 2019

Faculty

cover img faculity

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

cover img faculity

Anton L. Pozniak, MD, FRCP

Consultant Physician
Director of HIV Services

Department of HIV and Genitourinary Medicine
Chelsea and Westminster Hospital NHS Foundation Trust
London, United Kingdom

Provided by

ProCE Banner

Supporters

Gilead

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner